Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
12:44:30 EDT Sat 18 May 2024
Enter Symbol
or Name
USA
CA



Q:PHRRF - PHARMATHER HOLDINGS LTD - http://pharmather.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
PHRRF - Qnot subscribed0.16145.423230.1793  0.1793  0.160.32  0.061615:53:26May 1515 min RT 2¢

Recent Trades - Last 10 of 23
Time ETExPriceChangeVolume
15:53:26Q0.16 4,565
15:53:15Q0.16 150
15:53:15Q0.16 2,500
15:23:00Q0.16020.00025,990
13:37:39Q0.164750.004752,000
13:20:02Q0.16020.000280,610
13:19:59Q0.16020.00026,200
13:19:59Q0.16450.0045500
13:19:58Q0.16930.00931,000
13:19:58Q0.16450.0045500

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-15 08:00U:PHRRFNews ReleasePharmaTher's Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine
2024-05-10 07:59U:PHRRFNews ReleasePharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine
2024-05-01 08:00U:PHRRFNews ReleasePharmaTher's Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
2024-04-18 16:00U:PHRRFNews ReleasePharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
2024-04-16 08:00U:PHRRFNews ReleasePharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
2024-04-02 07:30U:PHRRFNews ReleaseRevive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
2024-02-21 09:30U:PHRRFNews ReleasePharmaTher ¢ € ™s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia
2024-02-12 08:00U:PHRRFNews ReleasePharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
2024-01-10 07:30U:PHRRFNews ReleasePharmaTher Provides Update for Expected FDA Approval of Ketamine
2023-09-27 07:30U:PHRRFNews ReleasePharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX ¢ „ ¢ (Ketamine)
2023-09-06 07:30U:PHRRFNews ReleasePharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX ¢ „ ¢ (Ketamine) to the FDA
2023-07-18 07:30U:PHRRFNews ReleasePharmaTher Announces Positive Research Results for PharmaPatch ¢ „ ¢ with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics
2023-06-27 07:00U:PHRRFNews ReleasePharmaTher Initiates Filing of Abbreviated New Drug Application for KETARX ¢ „ ¢ (racemic ketamine) to the FDA
2023-06-20 07:00U:PHRRFNews ReleasePharmaTher and Vitruvias Enter Into Collaboration Agreement for Commercialization of KETARX ¢ „ ¢ (racemic ketamine) in the U.S.
2023-06-12 07:00U:PHRRFNews ReleasePharmaTher Holdings Provides Corporate Update